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Background: The extracellular calcium-sensing receptor (CaSR) is distributed throughout the gastrointestinal
tract, and its activation has been shown to promote intestinal homeostasis, suggesting that CaSRmay be a prom-
ising target for novel therapies to prevent chronic intestinal inﬂammation such as inﬂammatory bowel disease
(IBD). The γ-glutamyl dipeptidesγ-glutamyl cysteine (γ-EC) andγ-glutamyl valine (γ-EV) are dietary ﬂavor en-
hancing compounds, and have been shown to activate CaSR via allosteric ligand binding. The aim of this study
was to examine the anti-inﬂammatory effects of γ-EC and γ-EV in vitro in intestinal epithelial cells and in a
mouse model of intestinal inﬂammation.
Results: In vitro, treatment of Caco-2 cells with γ-EC andγ-EV resulted in the CaSR-mediated reduction of TNF-α-
stimulated pro-inﬂammatory cytokines and chemokines including IL-8, IL-6, and IL-1β, and inhibited phosphor-
ylation of JNK and IκBα, while increasing expression of IL-10. In vivo, using a mouse model of dextran sodium
sulfate (DSS)-induced colitis, γ-EC and γ-EV treatment ameliorated DSS-induced clinical signs, weight loss,
colon shortening and histological damage. Moreover, γ-EC and γ-EV reduced the expression of TNF-α, IL-6,
INF-γ, IL-1β, and IL-17, and increased the expression of IL-10 in the colon, in a CaSR-dependent manner. The
CaSR-mediated anti-inﬂammatory effects of γ-EC were abrogated in β-arrestin2 knock-down Caco-2 cells, and
involvement of β-arrestin2was found to inhibit TNF-α-dependent signaling via cross-talk with the TNF-α receptor
(TNFR).
Conclusions: Thus CaSR activation by γ-EC and γ-EV can aid inmaintaining intestinal homeostasis and reducing in-
ﬂammation in chronic inﬂammatory conditions such as IBD.© 2015 Elsevier B.V. All rights reserved.1. Introduction
The calcium-sensing receptor (CaSR), a member of the G-protein-
coupled receptor (GPCR) family, detects extracellular calcium ions and
regulates the release of intracellular calcium, a secondary signaling
molecule involved in intracellular signal transduction. CaSR is widely
distributed in diverse cell types in various tissues including the parathy-
roid, brain, kidney, lung and bone marrow, where it regulates cellular
activities including secretion, apoptosis, proliferation, differentiation
and ion-channel activity [1,2]. CaSR is also present in the gastrointestinal
tract, and is expressed on the apical and basolateralmembranes of villous-protein-coupledreceptor; IBD,
erative colitis; γ-EC, γ-glutamyl
TNF-receptor-associatedfactor;
-1, monocyte chemoattractant
binding-protein; TLR, Toll-like
; fax: +1 519 824 6631.and crypt epithelial cells of the small intestine and colon, respectively,
where it is involved in the regulation of various processes such as intesti-
nal absorption, secretion andmotility [3,4]. Studies have shown that CaSR
plays a key role inmaintaining and restoring intestinal homeostasis [5,6],
and calcium-induced activation of CaSRwas found to promote differen-
tiation of colonic myoﬁbroblasts and stimulate regeneration of the in-
testinal barrier [6], suggesting that CaSR may be a promising target for
treating intestinal inﬂammation.
Inﬂammatory bowel disease (IBD), which includes Crohn's disease
(CD) and ulcerative colitis (UC), is a chronic relapsing inﬂammation of
the gastrointestinal tract [7]. Increased expression of inﬂammatorymedi-
ators during IBD results in the recruitment and activation of immune
cells, including neutrophils and lymphocytes, perpetuating the inﬂam-
matory response. TNF-α plays a predominant role in IBD pathogenesis
[8,9], and a number of anti-TNF-α therapies have been shown to success-
fully reduce pathology and morbidity in IBD patients [10].
GPCR agonists have been shown to exert anti-inﬂammatory effects
and interfere in TNF-α-stimulated signaling pathways [11,12]. The use
of exogenous ligands to modulate CaSR signaling is of great therapeutic
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spermine were recently found to reduce LPS-stimulated TNF-α secre-
tion in mouse macrophage cells [14]. L-amino acids and γ-glutamyl
peptides have been identiﬁed as CaSR agonists [15–17], however their
role in modulating intestinal inﬂammation has not been addressed.
The γ-glutamyl dipeptides γ-glutamyl cysteine (γ-EC) and γ-glutamyl
valine (γ-EV) are dietary ﬂavor enhancing compounds that have been
isolated from various sources, including edible beans [18] and yeast
extracts [19]. γ-Glutamyl dipeptides are also involved in glutathione
(GSH) metabolism, which plays an important role in antioxidant de-
fense, and γ-EC in particular is a crucial intermediate in GSH synthesis
[20]. Bothγ-EC andγ-EV have been shown to activate CaSR via allosteric
ligand binding [17], andmay therefore be useful for reducing inﬂamma-
tion and restoring intestinal homeostasis in IBD.
Upon ligand activation of GPCRs, signal transduction is regulated by
β-arrestins, adaptor proteins that bind receptors phosphorylated by G
protein-coupled receptor kinases (GRKs) [21]. β-arrestins couple GPCRs
to various downstream signaling components including mitogen-
activated protein kinases (MAPK) such as JNK, ERK 1/2, and p38 MAPK,
as well as IκBα and TNF-receptor-associated factor (TRAF) 6 [22,23].
β-Arrestins can alsomediate crosstalk betweenGPCR-induced signaling
and other receptors, such as the TNF-α receptor (TNFR), and lead to the
inhibition of inﬂammatory signaling pathways [11].
In the present study we demonstrated that γ-EC- and γ-EV-mediated
activation of CaSR reduces inﬂammatory mediator expression in vitro in
intestinal epithelial cells (IECs), by inhibiting JNK and IκBα phosphoryla-
tion, and improves clinical and histological parameters and reduces pro-
inﬂammatory cytokine and chemokine responses in a mouse model of
experimental colitis. Furthermore, we have shown that CaSR activation
by γ-EC can prevent TNF-α-induced pro-inﬂammatory signaling via
cross-talk with TNFR in a β-arrestin-dependent manner.2. Materials and methods
2.1. Cell culture and treatment
Human colorectal adenocarcinoma-derived intestinal epithelial cells
(Caco-2) (ATCC, Manassas, VA) were grown in DMEM/F12 (Gibco/Life
Technologies, Grand Island, NY) supplemented with 1 mM sodium
pyruvate (Gibco/Life Technologies), 20% FBS (HyClone, Logan, UT) and
50 U/mL penicillin–streptomycin (Gibco/Life Technologies). For treat-
ment with CaSR agonists/antagonists, cells between passages 15–45
were seeded at a density of 1 × 105 cells/well in 24- or 48-well plates
(Corning, Lowell, MA) and grown for 5–7 days. The CaSR agonists γ-EC
and γ-EV, and the CaSR antagonist NPS-2143, were kindly provided by
Ajinomoto Co., Ltd. (Kawasaki, Japan). Conﬂuent cell monolayers were
rinsed with Hank's buffered salt solution and treated with γ-EC or γ-EV
in culture medium containing 5% FBS for 2 h. For dose determination ex-
periments cells were treated with 0.01, 0.1, or 1mM γ-EC or γ-EV; for all
other experiments a concentration of 0.5 mM γ-EC or γ-EV was used.
Cells were stimulated with recombinant human TNF-α (2 ng/mL)
(Invitrogen/Life Technologies) to induce inﬂammation. To block CaSR ac-
tivation, cells were pre-treated with NPS-2143 (1 μM) for 45 min before
addition of γ-EC or γ-EV.2.2. Animals
6–8-week-old female BALB/c mice (16–20 g) (Charles River Labora-
tories Inc., Montreal, Quebec) were group housed on a 12-h light–dark
cycle and allowed unrestricted access to standard mouse chow and
water. All animal studies were approved by the University of Guelph
Animal Care Committee and carried out in accordancewith the Canadian
Council on Animal Care Guide to the Care and Use of Experimental
Animals.2.3. Treatment of mice with CaSR agonists/antagonists and induction of
DSS-induced colitis
Micewere administeredγ-EC orγ-EV (50 or 150mg/kg bodyweight
in 100 μL of water) or vehicle, by oral gavage, starting on day 1 and
continuing until day 14. On day 7, colitis was induced by the addition
of 5% dextran sodium sulfate (DSS) (MW 36–50 kDa, MP Biomedicals,
Solon, OH) to drinking water and continued until day 14. Negative con-
trol mice received water only, and positive control mice received DSS
only. For NPS-2143 treatment, mice were injected i.v. with 1 mg/kg
NPS-2143, dissolved in 20% 2-hydroxypropyl-β-cyclodextrin
(Sigma-Aldrich, St. Louis, MO), as a 30 μL bolus into the tail vein. One
hour after NPS-2143 injection mice were administered γ-EC or γ-EV
(150 mg/kg) by oral gavage. Mice were euthanized on day 14. Colons
were removed and measured, and tissue sections were ﬂash frozen or
stored in RNAlater® (Ambion/Life Technologies) for further analysis.
A section of distal colonwas ﬁxed in 10% buffered formalin for histolog-
ical analysis.2.4. Clinical analysis of colitis
Micewereweighed daily, and data are expressed asmean percentage
change relative to starting body weight. Mice were monitored daily for
stool consistency, presence of blood in stool or bleeding and general ap-
pearance, and a clinical activity score (ranging from0 to 7)was calculated
as described by Maxwell et al. [24].2.5. Histological analysis of colitis
Parafﬁn-embedded sections of distal colon were stained with hema-
toxylin and eosin (H&E) (Animal Health Laboratory, University of Guelph,
Guelph, Ontario), and histological scoring to assess colonic tissue injury
and inﬂammation was performed as described by Maxwell et al. [24].2.6. Cytokine ELISAs
Measurement of IL-8 in Caco-2 culture supernatants was carried out
as previously described [25]. Measurement of TNF-α and IL-6 concen-
trations in mouse colon tissues, tissues were homogenized in three
volumes of ice-cold PBS containing 1 mM PMSF, 10 μg/mL aprotinin,
10 μg/mL leupeptin, and 10 μg/mL pepstatin A (Sigma-Aldrich) using a
Polytron® homogenizer (PT 1200, Kinematica Inc., Bohemia, NY) and
centrifuged at 12,000 ×g for 10 min at 4 °C. Protein concentration was
measured by DC Protein Assay (Bio-Rad Laboratories, Inc., Hercules,
CA). TNF-α and IL-6 ELISAs were carried out using anti-mouse IL-6
(MP5-20F3) or anti-mouse/rat TNF-α (TN3-19.12) and biotinylated
anti-mouse IL-6 (32C11) or biotinylated anti-mouse TNF-α (C1150-
14) (BD Biosciences, San Jose, CA) according to the manufacturer's
instructions.2.7. RNA isolation and real-time RT-PCR
Total RNAwas extracted from cells using the Aurum™ Total RNAMini
Kit (Bio-Rad) according to the manufacturer's instructions. Mouse colon
tissues were homogenized in TRIZOL® Reagent (Invitrogen/Life Technol-
ogies) according to the manufacturer's instructions, and total RNA was
extracted from the aqueous phase using the Aurum Total RNA Mini Kit.
RNA (1 μg) was reverse transcribed using a qScript™ cDNA Synthesis
Kit (Quanta Biosciences, Inc., Gaithersburg, MD) and real-time quantita-
tive PCR was carried out as previously described [26] using the primers
listed in Supplemental Table S1. Relative gene expression was calculated
using the 2−ΔΔCtmethod [27] usingGAPDHas the reference gene. Results
are presented as fold expression change relative to negative control.
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Total intracellular GSH in Caco-2 cells was measured according
the method of Allen et al. [28], with modiﬁcations. Following treat-
ment in 24-well plates, cells were lysed with 400 μL of ice cold 0.1%
Triton X-100 (Sigma-Aldrich) and then combined with 200 μL of 5%
5-sulfosalicylic acid (Sigma-Aldrich) for 2 min at room temperature.
Sampleswere centrifuged at 8000×g for 10min at 4 °C. Protein concen-
tration of lysates was measured by DC Protein Assay (Bio-Rad). Lysates
(25 μL) were mixed with 125 μL of sodium phosphate buffer (143 mM)
containing 4 mM EDTA, 0.2 mM NADPH, 0.5 mM 5,5′-dithiobis(2-
nitrobenzoic acid) (DTNB), and 100 U/mL of GSH reductase (all from
Sigma-Aldrich), and incubated for 5 min at room temperature. Absor-
bance was measured at 405 nm. GSH concentration was determined
from a GSH standard curve.
2.9. Western blot analysis
Following treatment, cells were washed twice with cold PBS and
lysed in ice-cold RIPA buffer (ThermoFisher, Waltham, MA) containing
Halt™ Protease and Phosphatase Inhibitor Cocktail (ThermoFisher).
Cell lysates were sonicated for 5 min and centrifuged at 10,000 ×g for
25 min, and protein concentration was measured by DC Protein Assay.
Samples (30–50 μg of protein) were separated by SDS-PAGE (10%)
and transferred to a nitrocellulose membrane (Bio-Rad). Membranes
were blocked using 5% non-fat milk powder in TBS, and incubated
with primary antibody, at a dilution of 1:1000 or 1:2000, overnight at
4 °C. Antibodies used were: anti-p-SAPK/JNK (81E11), anti-SAPK/JNK
(56G8), anti-p-IκBα (5A5) (Cell Signaling Technology, Inc., Danvers,
MA), anti-IκB-α (H-4), anti-p-p38 (D-8), and anti-p38α/β (A-12) (Santa
Cruz Biotechnology, Santa Cruz, CA). HRP-conjugated anti-mouse or
anti-rabbit IgG (Promega, Madison, WI) was used at a dilution of
1:10,000. Proteins were detected using ECL Western Blotting Detection
Reagent (GE Healthcare) and densitometry was performed using Image
J software (Image Processing and Analysis in Java, National Institutes of
Health, http://rsbweb.nih.gov/ij/). In order to verify the activation of
IκBα, JNK or P38 signaling pathways involved in regulating TNF-α-
induced signaling cascades, Caco-2 cells were stimulated by 2 ng/mL
TNF-α for 2 h after pretreated with or without inhibitors including
SB203580 (25 μM) (CAS 152121-47-6, Santa Cruz Biotechnology, Inc.),
Bay11-7082 (50 μM) (CAS 19542-67-7) or SP600125 (50 μM) (CAS129-
56-6) for 30 min. The production of IL-8 and phosphorylation of P38,
IκB or JNK were assayed by ELISA andWestern blot analysis, respectively
as described above.
2.10. siRNA transfection
Caco-2 cells were transiently transfected with β-arrestin-2 or nega-
tive control siRNA using Lipofectamine® LTX and Plus™ Reagent
(Invitrogen/Life Technologies) according to the manufacturer's instruc-
tions. Cells were cultured in 24- or 6-well plates until 60–80% conﬂuency
was reached. siRNA targeting human β-arrestin-2 (Hs ARRB2-3 siRNA)
(QIAGEN, Germantown, MD) or negative control siRNA (Scramble)
(QIAGEN) (0.5 μg or 2.5 μg per well for 24- or 6-well plates, respectively)
were diluted in 100 μL Opti-MEM® I medium (Invitrogen/Life Technolo-
gies) and incubated for 15 min at room temperature with 0.5 or 2.5 μL
PLUS Reagent. Lipofectamine LTX (1.5 μL or 6 μL) was diluted in 100 μL
Opti-MEM® I medium and added to the siRNA solution, and the mixture
was incubated for 25min at room temperature. The transfectionmixture
was diluted in 400 or 800 μL Opti-MEM® I, respectively, and added to
the cells in 24- or 6-well plates. After 6–8 h, 0.5 or 1 mL of DMEM/F12
medium containing 2× FBS, 1 mM sodium pyruvate, and 50 U/mL
penicillin–streptomycin was added directly to each well of a 24- or
6-well plate. After 48 h, cells were treated with γ-EC and TNF-α as
previously described. Culture supernatants were collected for ELISA
and cells were harvested for Western blotting.2.11. Co-immunoprecipitation analysis
Cells were harvested 30 min after TNF-α stimulation and immuno-
precipitation was carried out according to the manufacturer's instruc-
tions using a Pierce Crosslink Immunoprecipitation Kit (ThermoFisher).
Brieﬂy, anti-β-arrestin-2 (C16D9)(Cell Signaling) or anti-TAK1 (H-5)
antibodies (Santa Cruz Biotechnologies) (2 μg–10 μg) were cross-
linked to protein A/G-agarose beads, and incubatedwith pre-cleared ly-
sate (550 μg of total protein) for 2 h at room temperature. The eluted
antigen was analyzed by Western blot analysis using anti-TAB1
(25E9) (Cell Signaling) or anti-CaSR (H-100) (Santa Cruz Biotechnolo-
gy) antibodies.
2.12. Statistical analysis
Data are expressed as means ± SEM. Statistical analyses were per-
formed with GraphPad Prism version 5.0 (GraphPad, San Diego, CA)
using one-way ANOVA followed by Dunnett's test to compare groups
to a control, or two-way ANOVA followed by Tukey's post test, as indi-
cated. Unpaired Student's t test was used when comparisons between
only two groups were carried out. Differences were considered signiﬁ-
cant when p b 0.05.
3. Results
3.1. γ-EC and γ-EV Reduce Expression of TNF-α-induced Inﬂammatory
Mediators in Intestinal Epithelial Cells
We ﬁrst examined the potential anti-inﬂammatory properties of
γ-EC and γ-EV using an in vitromodel of TNF-α-induced inﬂammation
in Caco-2 IECs. Cells were treated with γ-EC or γ-EV, and TNF-α was
added to induce inﬂammation. Stimulation of Caco-2 cells with TNF-α
increases the expression of inﬂammatory mediators, including IL-8
[29], which was used here as a marker of inﬂammation. Pre-treatment
with γ-EC or γ-EV signiﬁcantly reduced TNF-α-induced IL-8 secretion
from Caco-2 cells in a dose-dependent manner, reducing IL-8 concen-
trations up to 6-fold when used at the highest dose (1 mM) (Fig. 1A).
Likewise, treatment with γ-EC or γ-EV signiﬁcantly reduced mRNA
levels of IL-8, as well as pro-inﬂammatory cytokines TNF-α, IL-6, and
IL-1β, when compared to cells treated with TNF-α alone (Fig. 2B–E). A
signiﬁcant increase in the expression of the anti-inﬂammatory cytokine
IL-10 was also observed in response to γ-EC and γ-EV treatment
(Fig. 1F). The expression of CaSR in Caco-2 cells following treatment
with TNF-α, γ-EC and γ-EVwas alsomeasured, and no signiﬁcant effect
of treatment was observed on CaSR expression at both the gene and
protein levels when compared to untreated control cells (data not
shown). Serial concentrations of CaCl2 (0.1, 0.5, 1.0, 2.5 and 5 mM)
were supplemented to DMEM/F12 10% FBS medium (Ca2+ level is
1.05 mM) with or without 0.5 mM γ-EC or γ-EV, and incubated with
Caco-2 cells for 2 h before adding 2 ng/mL TNF-α (Fig. 2). A signiﬁcant
decrease of IL-8 level was detected in 2.5 mM or 5 mM CaCl2 treated
Caco-2 cells after sole TNF-α stimulation as shown in Fig. 2. The result
ﬁrstly conﬁrmed that calcium as orthosteric agonist for CaSR activation
has anti-inﬂammatory activity to reduce TNF-α-induced inﬂammation
in Caco-2 cells at a relatively high concentration comparedwith allosteric
agonistsγ-EC orγ-EV.However, the inhibitory activity ofγ-EC orγ-EVon
IL-8 secretion was not signiﬁcantly affected by an increase of calcium
concentrations.
Since γ-glutamyl dipeptides, in particularγ-EC, are precursors in the
synthesis of GSH, a major antioxidant in mammalian cells, we next
examinedwhether the addition ofγ-EC andγ-EVmay have led to an in-
crease in cellular GSH levels, thereby reducing inﬂammatory responses.
Treatment of Caco-2 cellswith TNF-α, γ-EC or γ-EV did not signiﬁcantly
affect intracellular GSH concentrations (data not shown), suggesting
that increased GSH synthesis was not a major contributor to the anti-
inﬂammatory effects of γ-EC and γ-EV observed here.
Fig. 1. γ-EC and γ-EV reduce TNF-α-stimulated pro-inﬂammatory cytokine expression
and increase IL-10 expression in Caco-2 cells. A, Caco-2 cells were pre-treated for 2 h
with γ-EC or γ-EV at indicated doses, followed by stimulation with 2 ng/mL TNF-α for
4 h. IL-8 concentration in supernatants was measured by ELISA. Data are presented as
mean ± SEM (n = 4 independent determinations). B–F, Caco-2 cells were pre-treated
for 2 h with 0.5 mM of γ-EC or γ-EV followed by stimulation with 2 ng/mL TNF-α for
4 h. mRNA expression was measured by real-time quantitative RT-PCR using GAPDH as
the reference gene, and results are expressed as mRNA level relative to control. Data are
presented as mean ± SEM (n = 6 independent determinations). *p b 0.05; **p b 0.01;
***p b 0.001 versus TNF-α alone using one-way ANOVA with Dunnett's post test.
Fig. 2. Calcium, γ-EC and γ-EV reduce TNF-α-stimulated IL-8 expression in Caco-2 cells.
Caco-2 cells were pre-treated for 2 h with supplemental calcium with or without γ-EC
or γ-EV at indicated doses, followed by stimulation with 2 ng/mL TNF-α for 4 h. IL-8 con-
centration in supernatants wasmeasured by ELISA. Data are analyzed by one-way ANOVA
within each group and presented as mean ± SEM (n = 3 independent experiments).
*p b 0.05; **p b 0.01 versus TNF-α alone.
Fig. 3. TNF-α-induced IL-8 secretion in Caco-2 cell via activation of NF-κB and MAPK
pathways. Caco-2 cells were stimulated by 2 ng/mL TNF-α for 2 h after being
pretreated with or without inhibitors including SB203580 (25 μM), Bay11-7082
(50 μM) or SP600125 (50 μM) for 30 min. The production of IL-8 and phosphorylation
of P38, IκB or JNK were assayed by ELISA and Western blot analysis, respectively. Data
are presented as means ± SEM (n = 3), ***p b 0.001 versus sample without inhibitors.
###p b 0.001 or #p b 0.5 versus TNF-α alone.
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At ﬁrst in order to verify the activation of IκBα, JNK or P38 signaling
pathways involved in regulating TNF-α-induced signaling cascades, a se-
ries of pharmacologic inhibitors, including Bay11-7082, SP600125 and
SB203580 were subjected in this experiment to block the TNF-α-
mediated activations of IκBα, JNK or P38 in Caco-2 cells, respectively.
The secretion of IL-8 from TNF-α-treated Caco-2 cells was completely ab-
rogated by Bay11-7082 and markedly inhibited by SP600125, but not
SB203580 as shown in Fig. 3. The TNF-α-induced phosphorylation of
IκBα or JNK was abrogated by Bay11-7082 or SP600125. However,pretreatmentwith SB203580 inhibitor did not demonstrate similar inhib-
itory effects on phosphorylation of P38. The results suggest that IκBα and
JNK were dominantly involved in TNF-α-initiated signaling cascades.
Since both peptides exhibited similar effects on cytokine expression as
shown in Fig. 1, and γ-EC has been shown to be a stronger CaSR agonist
than γ-EV in vitro [17,18], it was selected for use in further cell signaling
experiments. To examine the effects of g-glutamyl peptides on TNF-α-
stimulated MAPK and NF-κB activation, Caco-2 cells were ﬁrst treated
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of total cell lysates using phospho-speciﬁc antibodies revealed that
TNF-α-induced phosphorylation of JNK and IκBα was signiﬁcantly
reduced by γ-EC (γ-EC + TNF-α) when compared to cells treated
with TNF-α alone (TNF-α) (Fig. 4A and B). p38 phosphorylation was
low in all treatments, and only a slight decreasewas observed following
γ-EC treatment. There was no effect of peptide alone (γ-EC) on JNK,
IκBα, or p38 phosphorylation. Taken together with the cytokine data,
these results suggest that treatment of Caco-2 cells with γ-EC or γ-EV
may prevent TNF-α-induced activation of the JNK pathway and NF-κB
transcriptional activity, thereby reducing the production of inﬂamma-
tory mediators.
3.3. The CaSR antagonist NPS-2143 abrogates the anti-inﬂammatory effects
of γ-EC and γ-EV in Caco-2 IECs
Since γ-EC and γ-EV are known CaSR agonists, we then sought to
conﬁrm that the observed anti-inﬂammatory effects were mediated
via CaSR. To this end, pre-treatment with NPS-2143, a CaSR-speciﬁc an-
tagonist, was used to blockCaSR activation byγ-EC andγ-EV.NPS-2143,
a negative allosteric regulator of CaSR, been usedwidely in in vitro stud-
ies to inhibit CaSR agonist-induced signaling cascades [30,31]. Here, we
observed that pre-treatment of Caco-2 cells with NPS-2143 prior to the
addition of γ-EC or γ-EV abrogated the anti-inﬂammatory effect of the
peptides, and restored TNF-α-induced IL-8 secretion in cells treated
with γ-EC or γ-EV (Fig. 5A). The signiﬁcant difference between
NPS-2143 pretreatment and TNF-α treatment alone was not observed,
which suggests that CaSR-mediated signaling cascade is primarily in-
volved in blocking TNF-α-initiated inﬂammatory response (data not
shown). Likewise, NPS-2143 prevented the inhibitory effect of γ-EC
on the TNF-α-stimulated phosphorylation of JNK and IκBα (Fig. 5B
and C) in Caco-2 cells.
3.4. γ-EC and γ-EV reduce the severity of inﬂammation in amousemodel of
DSS-induced colitis
To investigatewhether theγ-glutamyl peptidesγ-EC andγ-EV could
also prevent inﬂammation in vivo, a mousemodel of DSS-induced colitis
was used. Mice were orally administered γ-EC or γ-EV for 14 days, and
DSS was introduced into the drinking water on day 7 to induce colitisFig. 4. TNF-α-stimulated phosphorylation of JNK and IκB is reduced by γ-EC. Caco-2 cells wer
30min. A, Western blot analysis of cell lysates was performed using antibodies against phosph
iment of six is shown). B, quantitative analysis of relative levels of phosphorylated JNK, IκB, an
untreated control cells. Data are presented as mean ± SEM (n = 6 independent determinatio
Dunnett's post test.(Fig. 6A). On day 14, tissues were collected for analysis. After receiving
DSS for 7 days, positive control mice (Pos) displayed characteristic
signs of colitis including weight loss, diarrhea and rectal bleeding
when compared to untreated control mice (Neg). Mice receiving γ-EC
or γ-EV (50 or 150 mg/kg) for 14 days showed signiﬁcantly reduced
clinical signs when compared to Pos mice (Fig. 4B). Treatment with
γ-EC and γ-EV also attenuated DSS-induced weight loss (in all
groups except 150 mg/kg γ-EC) (Fig. 6C) and colon shortening
(Fig. 6D and E). Histopathological evaluation of H&E-stained colon
sections revealed loss of mucosal architecture, inﬁltration of inﬂamma-
tory cells into the mucosa and submucosa, and intense cellular inﬂam-
mation in all layers of colonic tissue in DSS-treated positive control
mice. Signiﬁcantly less tissue damage, cellular inﬁltration and mucosal
ulceration was observed in mice treated with γ-EC (150 mg/kg) or
γ-EV (50 and 150 mg/kg) as compared to the Pos control group
(Fig. 6F and G).
There was no signiﬁcant difference of clinical signs identiﬁed
between two dosages treated groups of mice in Fig. 6B, but a signiﬁcant
difference of weight changes, colon shortening and histological score in
the group of mice treated with 150 mg/kg BW γ-EV was only observed
in this study.
The effect of γ-EC and γ-EV administration on DSS-induced inﬂam-
matory cytokines in the colon was also examined. Concentrations of
TNF-α and IL-6 in colon tissue homogenates were measured by ELISA.
Both doses of γ-EC and γ-EV signiﬁcantly reduced TNF-α production
when compared to Pos mice (Fig. 7A). While IL-6 concentrations were
reduced in all groups, only the high dose of γ-EC (150 mg/kg) resulted
in a signiﬁcant reduction in IL-6, despite marked weight loss observed
in this group. The anti-inﬂammatory effect of γ-EC and γ-EV on
DSS-induced inﬂammation in the colon was most evident in the
mRNA expression levels of key inﬂammatory mediators. Analysis
using qRT-PCR revealed that relative mRNA expression of TNF-α,
IL-6, IFN-γ, IL-1β, and IL-17A was signiﬁcantly reduced in mice treated
with either dose ofγ-EC orγ-EV (Fig. 7B-F), aswas the expression of the
chemokine monocyte chemoattractant protein (MCP)-1 (Fig. 7G).
Moreover, bothγ-EC andγ-EV signiﬁcantly increasedmRNA expression
of IL-10 (Fig. 7H). Therewas no effect of the peptides alone on any of the
parameters measured (data not shown). There was no dose–response
existing in current study exceptMCP-1 and IL-10 gene expression treat-
ed with γ-EC. These ﬁndings are in line with our in vitro results in IECs,e pre-treated for 2 h with 0.5 mM γ-EC, followed by stimulation with 2 ng/mL TNF-α for
o-JNK, JNK, phospho-IκB, IκB, phospho-p38, and p38 (images of one representative exper-
d p38 using ImageJ software. Results are expressed as relative protein levels compared to
ns). *p b 0.05; ⁎⁎p b 0.01; ⁎⁎⁎p b 0.001 versus TNF-α alone using one-way ANOVA with
Fig. 5.NPS-2143 blocks anti-inﬂammatory effects ofγ-EC andγ-EV in Caco-2 cells. Caco-2 cellswere pre-treatedwith 1 μMNPS-2143 for 45min, followedby incubationwith 0.5mMγ-EC
or γ-EV for 2 h. Cells were then stimulated with 2 ng/mL TNF-α for 30 min (Western blotting) or 4 h (ELISA). A, IL-8 concentration in supernatants was measured by ELISA. Data are
presented as mean ± SEM (n = 4 independent determinations). ***p b 0.001 versus peptide treatment without inhibitor using unpaired Student's t test. ###p b 0.001 versus TNF-α
alone using one-way ANOVA with Dunnett's post test. B, Western blot analysis of cell lysates was performed using antibodies against phospho-JNK, JNK, phospho-IκB, and IκB (images
of one representative experiment of six is shown). C, quantitative analysis of relative levels of phosphorylated JNK and IκB using ImageJ software. Results are expressed as relative protein
levels compared to untreated control cells. Data are presented asmean±SEM(n=6 independent determinations). ***p b 0.001 versuspeptide treatmentwithout inhibitor using unpaired
Student's t test. ###p b 0.001 versus TNF-α alone using one-way ANOVA with Dunnett's post test.
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effects in vivo.3.5. γ-EC and γ-EV reduce DSS-induced pro-inﬂammatory cytokine
expression via CaSR activation
Based on the previous in vitro and in vivo results, we next examined
if the ability of γ-EC and γ-EV to reduce the severity of DSS-induced
inﬂammation in mice was similarly mediated by CaSR. The use of
NPS-2143 has been reported to block CaSR activation in rat and
mousemodels, andwas found to inhibit CaSR-mediated gastrin secretion
in the stomach ofmice following i.v. administration [32], and sowas used
here to block CaSR activation by the γ-glutamyl peptides in a mouse
model of DSS-induced colitis. NPS-2143 or vehicle was given daily before
oral administration of γ-EC and γ-EV for 14 days (Fig. 8A). After 7 days of
DSS administration, relative mRNA expression in the colon was mea-
sured. Treatment with NPS-2143 restored DSS-induced mRNA expres-
sion of TNF-α, INF-γ, IL-6, IL-1β, and IL-17A when compared to mice
treated without inhibitor (Fig. 8B–F), suggesting that NPS-2143 also
interfered with the anti-inﬂammatory effects of the peptides in vivo.
NPS-2143 also prevented the γ-EC- and γ-EV-induced increase in IL-10
expression (Fig. 8G), although this effect was not as pronounced as
with the other cytokines. These results conﬁrm that γ-EC and γ-EVcan reduce DSS-induced inﬂammation via CaSR-mediated signaling
pathways.3.6. Role of β-arrestin2 in the CaSR-mediated anti-inﬂammatory effects of
γ-glutamyl peptides
β-Arrestin2 has been shown to be involved in the regulation of CaSR
function [33] and participate in downstream anti-inﬂammatory sig-
nalingmechanisms in immune cells [11]. Thus, we hypothesized that
β-arrestin2 may similarly be involved in the CaSR-mediated signaling
events observed here. To determine whether β-arrestin2 was required
for the anti-inﬂammatory effects of γ-EC, Caco-2 cells with reduced
β-arrestin2 expression were generated. Caco-2 cells were transiently
transfected with speciﬁc β-arrestin2 siRNA, to produce β-arrestin2
knockdown cells (β-arr2 KD) (Fig. 9A) and the effect of γ-EC on
TNF-α-stimulated cytokine production and cell signaling was com-
pared to control cells transfected with control siRNA (Scramble). In
β-arrestin2 knockdown cells, the γ-EC-mediated anti-inﬂammatory
activity was reduced when compared to control cells (Scramble),
resulting in an increase in IL-8 levels in β-arr2 KD cells treated with
γ-EC and TNF-α (Fig. 9B). Although a decrease in TNF-α-stimulated
IL-8 secretion was still observed in response to γ-EC in the β-arr2
KD cells, this was to a lesser extent than that observed in control
Fig. 6. γ-EC and γ-EV reduce severity of histopathological and clinical parameters of DSS-induced colitis in mice. A, experimental design. Mice were given 50 or 150 mg/kg γ-EC or γ-EV
orally for 14 d. To induce acute colitis, 5% DSS was added to drinking water on day 7. B, clinical score was determined by assessing stool consistency, presence of blood in stool or rectal
bleeding, and general appearance. Clinical scores ranged from 0 to 7. Data is presented as mean score± SEM (n=12 per group). *p b 0.05 versus all other groups using one-way ANOVA
with Dunnett's post test. C, bodyweight loss after induction of colitis was calculated asmean percent of initial weight ± SEM (n=12 per group). †p b 0.05 for Pos versusNeg; *p b 0.05 for
Pos versusγ-EC 50; ‡p b 0.05 for Pos versus γ-EV 50; §p b 0.05 for Pos versusγ-EV 150 using unpaired Student's t test. D, length of colons from a)Neg, b) Pos, c)γ-EC 50, d)γ-EC 150, e)γ-EV 50,
and f) γ-EV 150 groups. Images are representative examples of each group. E, colon shortening is presented as mean change in percent colon length compared to Neg ± SEM (n= 12 per
group). *p b 0.05; **p b 0.01; ***p b 0.001 versus Pos. F, degree of ulceration, tissue damage and cellular inﬁltration in colons of a) Neg, b) Pos, c) γ-EC 50, d) γ-EC 150, e) γ-EV 50, and
f) γ-EV 150 groups. Images are representative examples of each group at 50× (upper panel) and 20× (lower panel)magniﬁcation. G, histological scoringwas carried out to assess colonic
tissue injury and inﬂammation. Data is presented as mean score ± SEM (n= 6 per group). *p b 0.05; **p b 0.01; ***p b 0.001 versus Pos using one-way ANOVA with Dunnett's post test.
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γ-EC to reduce TNF-α-stimulated phosphorylation of JNK and IκB was
also abolished in β-arrestin2-deﬁcient cells (Fig. 9C and D), suggesting
that β-arrestin2 expression is required for the anti-inﬂammatory activity
of γ-EC.We further investigated the role of β-arrestin2 with respect to
potential cross-talk between CaSR and TNFR-mediated signaling path-
ways. TGF-β-activated kinase 1 (TAK1) is an intermediate regulator in
the TNFR signaling pathway, and is activated by TNF-α, resulting in
the association of TAK1 with TAK1 binding protein (TAB1) and the
Fig. 7.γ-EC andγ-EV reduce expression of DSS-induced pro-inﬂammatorymediators inmice. A, TNF-α and IL-6 concentrations in colon homogenatesweremeasured by ELISA. Results are
expressed as cytokine amount per total protein concentration. Data are presented as mean ± SEM (n = 6 per group). *p b 0.05; **p b 0.01; ***p b 0.001 versus Pos. B, cytokine and
chemokine mRNA expression in the colon was measured by quantitative real-time RT-PCR using GAPDH as the reference gene. Results are expressed as mRNA level relative to untreated
(Neg) mice. Data are presented as mean ± SEM (n= 6 per group). *p b 0.05; **p b 0.01; ***p b 0.001 versus Pos using one-way ANOVA with Dunnett's post test.
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Lysates fromCaco-2 cells treatedwithγ-EC and/or TNF-αwere subjected
to immunoprecipitation using antibodies against β-arrestin2 or TAK1,
and co-immunoprecipitated proteins were detected by Western
blotting analysis using TAB1- or CaSR-speciﬁc antibodies. γ-EC treat-
ment resulted in association between β-arrestin2 and CaSR (Fig. 10A),
both in the presence or absence of TNF-α (Fig. 10A). γ-EC also causedthe interaction of β-arrestin2 with TAB1 (Fig. 10A), and reduced TNF-
α-stimulated TAK1–TAB1 complex formation (Fig. 10B). In similar co-
immunoprecipitation experiments using β-arr2 KD cells, γ-EC did not
reduce TNF-α-stimulated TAB1–TAK1 association in β-arrestin2-
deﬁcient cells, in contrast to the corresponding control cells (Scramble)
treatedwith both TNF-α and γ-EC (Fig. 10C). These results indicate that
the activation of CaSR by γ-EC leads to the association of β-arrestin2
Fig. 8.NPS-2143 reduces anti-inﬂammatory effects of γ-EC andγ-EV inDSS-induced colitis. A, experimental design. Micewere injected i.v. with 1mg/kgNPS-2143 or vehicle, followed by
treatment with γ-EC or γ-EV (150 mg/kg) by oral gavage for 14 d. To induce acute colitis, 5% DSS was added to drinking water on day 7. B, cytokine mRNA expression in the colon was
measured by quantitative real-time RT-PCR using GAPDH as the reference gene. Results are expressed as mRNA level relative to untreated (Neg) mice. Data are presented as mean ±
SEM (n= 6 per group). *p b 0.05 versus corresponding group receiving no NPS-2143 antagonist using unpaired Student's t test.
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TAB1–TAK1 binding and thereby preventing TNF-α-induced stimulation
of inﬂammatory pathways through TNFR, as illustrated in Fig. 11.
4. Discussion
Wehave demonstrated here thatγ-EC andγ-EV exert CaSR-mediated
anti-inﬂammatory activity in vitro in IECs and in a mouse model ofintestinal inﬂammation. In vitro, the intracellular signaling triggered
by γ-EC binding with CaSR interfered with TNF-α-stimulated pro-
inﬂammatory signaling events, inhibiting activation of both IκBα and
JNK pathways. We further demonstrated that γ-EC-induced activation
of CaSR led to the recruitment of β-arrestin2 and subsequent association
with TAB1, thereby interfering with TAK1-dependent inﬂammatory sig-
naling activated by extracellular TNF-α. This is also the ﬁrst such report
of interaction, or cross-talk, between CaSR and TNFR in IECs.
Fig. 9. Expression ofβ-arrestin2 is required for anti-inﬂammatory activity of γ-EC in Caco-2 cells. Caco-2 cells were transiently transfected with control siRNA (Scramble) or speciﬁc
β-arrestin2 siRNA to produceβ-arrestin2 knockdown cells (β-arr2 KD).β-arr2 KDor control (Scramble) Caco-2 cellswere pre-treated for 2 hwith 0.5mMofγ-EC followed by stimulation
with 2 ng/mL TNF-α for 30min (Western blotting) or 4 h (ELISA). A,β-arrestin2 knock-downwas conﬁrmed byWestern blotting, using β-actin as loading control. B, IL-8 concentration in
supernatantswasmeasuredby ELISA.Data are presented asmean±SEM (n=4 independent determinations). p b 0.001 for interaction, and p b 0.001 for treatment effects using two-way
ANOVA. **p b 0.01; ***p b 0.001 versus TNF-α alone. ##p b 0.01 versus control (Scramble) cells using Tukey's post test. C, Western blot analysis of cell lysates was performed using anti-
bodies against phospho-JNK, JNK, phospho-IκB, and IκB (images of one representative experiment of six is shown). D, quantitative analysis of relative levels of phosphorylated JNK and IκB
using ImageJ software. Results are expressed as relative protein levels compared to untreated control cells. Data are presented as mean ± SEM (n= 6 independent determinations).
p b 0.01 for interaction, p b 0.001 for treatment effects, and p = 0.053 (JNK) or p = 0.1 (IκB) for genotype effect (Scramble versus β-arr2 KD) using two-way ANOVA. *p b 0.05;
**p b 0.01; ***p b 0.001 versus TNF-α alone. ##p b 0.01 versus control (Scramble) cells using Tukey's post test.
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microﬂora result in damage to the intestinal epithelial barrier and acti-
vation of immune cells in the laminapropria, leading to the overproduc-
tion of pro-inﬂammatory cytokines [7,36]. The increased expression of
pro-inﬂammatory mediators including TNF-α and IFN-γ induces the
production of additional inﬂammatory cytokines such as IL-1β, IL-6
and IL-17. Current evidence suggests that TNF-α plays a key role in
IBD pathogenesis, disrupting intestinal homeostasis and preventing ac-
tivation of regulatory cells [9,37]. As such, TNF-α and its associated
pathways have become an important therapeutic target, and biological
therapies, including anti-TNF-α monoclonal antibodies, have been
shown to aid in successfully managing IBD symptoms in humans [10].
In vitro, reduction of TNF-α-associated expression of the chemokine
IL-8 by Caco-2 cells has been linked to inhibition of NF-κB activation,
and correlated with in vivo anti-inﬂammatory activity in mice [38].
Here, we observed that both γ-EC and γ-EV reduced TNF-α-induced
IL-8 secretion, as well as the expression of TNF-α-induced pro-
inﬂammatory mediators in vitro in Caco-2 cells. Moreover, γ-EC andγ-EV increased IL-10 expression, an anti-inﬂammatory or regulatory
cytokine important in maintaining intestinal homeostasis [39].
JNK, ERK 1/2, and p38MAPK and their related signaling components
play an important role in the perpetuation of the inﬂammatory re-
sponse in IBD, and MAPK inhibitors, including those against JNK and
p38 have been examined as possible IBD therapeutics in animal models
and human studies [40]. In Caco-2 cells, TNF-α similarly activatesMAPK
and NF-κB pathways, leading to the production of pro-inﬂammatory
mediators [41]. Treatment of Caco-2 cells with γ-EC reduced phosphor-
ylation of JNK and IκBα, which is necessary for NF-κB transcriptional ac-
tivation [42], in response to TNF-α. However, p38 was not affected by
either TNF-α or γ-EC treatment. This is consistent with reports that
dietary anti-inﬂammatory compounds can exert their effects by
blocking MAPK signaling and NF-κB activation [43], and a recent study
demonstrated that anti-inﬂammatory polyphenols could inhibit
TNF-α-stimulated JNK phosphorylation and NF-κB translocation in
Caco-2 cells, but did not prevent p38 or ERK activation [44]. This would
suggest that the in vitro anti-inﬂammatory activity of γ-glutamyl
Fig. 10. Effect ofγ-EC onTNF-α-stimulated TAB1–TAK1 association in Caco-2 cells. A, Caco-2 cellswere treated for 2 h in the presence or absence of 0.5mMofγ-EC followedby stimulation
with orwithout 2 ng/mL TNF-α for 30min. Cell lysateswere subjected to immunoprecipitation (IP) using anti-β-arrestin2 (β-arr2) antibodies, andWestern blotting (WB) was performed
using anti-CaSR or anti-TAB1 antibodies. B, Caco-2 cells were treated for 2 h in the presence or absence of 0.5 mM of γ-EC followed by stimulation with or without 2 ng/mL TNF-α for
30min. Cell lysates were subjected to immunoprecipitation (IP) using anti-TAK1 antibodies, andWestern blotting (WB) was performed using anti-TAB1 antibodies. C, β-arrestin2 knock-
down (β-arr2 KD) or control (Scramble) Caco-2 cells were pre-treated for 2 h in the presence or absence of 0.5 mM of γ-EC followed by stimulation with 2 ng/mL TNF-α for 30min. Cell
lysates were subjected to immunoprecipitation (IP) using anti-TAK1 antibodies, and Western blotting (WB) was performed using anti-TAB1 antibodies. An aliquot of the cell lysate was
also analyzed by Western blotting using antibodies against TAB1. Data are presented as mean ± SEM (n=3), *pb0.05 and ** pb0.01 versus TNF-α alone using one-way ANOVA with
Dunnett’s post test.
Fig. 11. Putative mechanism for CaSR-mediated anti-inﬂammatory effect of γ-EC in Caco-2
cells. Ligand activation of CaSR by γ-EC leads to phosphorylation of CaSR by GRK, resulting
in the interaction of β-arrestin2 with CaSR and TAB1, reducing TNF-α-induced TAB1–TAK1
complex formation and activation of JNK and IκB inﬂammatory pathways.
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and reduce NF-κB activation. CaSR is known to be expressed by intestinal
epithelial cell lines, including Caco-2 cells [45,46]. The CaSR-speciﬁc
antagonist NPS-2143 was employed here to conﬁrm that the anti-
inﬂammatory effects of γ-EC and γ-EV were mediated via activation of
CaSR. As expected, NPS-2143 abrogated the in vitro anti-inﬂammatory
effects of γ-EC and γ-EV, restoring IL-8 secretion, JNK and IκB phosphor-
ylation in Caco-2 cells treated with TNF-α. Similarly, activation of the
GPCR GPR120 in mouse macrophage cells was found to inhibit TNF-α-
mediated inﬂammatory responses, preventing phosphorylation of JNK
and IKKβ, IκB degradation, and inﬂammatory cytokine expression [11].
Amousemodel of DSS-induced colitis was used to evaluate the anti-
inﬂammatory effects ofγ-EC andγ-EV in vivo. DSS causes damage to the
intestinal epithelium and impairs gut barrier function by activating the
NF-κB pathway, leading to mucosal inﬂammation and ulceration,
neutrophil inﬁltration, colon shortening and diarrhea [47,48]. We have
previously shown that dietary di- and tri-peptides could reduce the
severity of inﬂammation and down-regulate the expression of pro-
inﬂammatory mediators in animal models of colitis [26,49]. Here, treat-
ment with γ-EC and γ-EV reduced DSS-induced clinical colitis signs,
colon shortening, and histological damage. Surprisingly, the high dose
of γ-EC did not reduce DSS-induced weight loss, despite an apparent
reduction in all other colitis parameters, suggesting that there might
be other potential effects of a high concentration of γ-EC on growth
rate which will need to be further examined. In line with our in vitro
results in Caco-2 cells, γ-EC and γ-EV also reduced the expression of
pro-inﬂammatory cytokines and chemokines in the colon, and up-
regulated the expression of IL-10. The in vivo anti-inﬂammatory effects
of γ-EC and γ-EV were likewise shown to be mediated by CaSR
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peptides may be effective for the reduction of intestinal inﬂammation.
To elucidate the mechanism by which γ-glutamyl dipeptides could
reduce TNF-α-stimulated inﬂammation, we examined the role of
β-arrestin-mediated signaling and cross-talk between CaSR and
TNFR. β-Arrestins can regulate immune responses by coordinating
NF-κB-dependent signaling pathways in cells, and association of
β-arrestins with IκBαhas been found to inhibitNF-κB transcriptional ac-
tivation in various cell types [22,50]. In the present study, the expression
of β-arrestin2 in Caco-2 cells was required for the anti-inﬂammatory
activity of γ-EC, and in particular JNK and IκB phosphorylation. Because
TNF-α-induced phosphorylation of both JNK and IκB was inhibited in
γ-EC-treated Caco-2 cells, it suggests that the underlying mechanism
may involve the interaction of β-arrestin2 with upstream signal pro-
teins in the TNF-α pathway. The importance of TNF-α and its receptor,
TNFR, in inﬂammation and IBD is well known [51]. Upon TNF-α binding
to TNFR, TNFR-associated factors (TRAFs) detach from the receptor and
form a trimeric complex with TAK1, TAB1 and TAB2, which mediates
activation of MAPKs and NF-κB signaling [52–54]. We therefore under-
took to examine the potential role of TAK1 involvement in cross-talk
between CaSR- and TNFR-mediated signaling pathways. TAB1 is an adap-
tor protein and plays a critical role to activate TAK1 [34], and recently it
was demonstrated that activation of the GPCR GPR120 could mediate
association between β-arrestin2 and TAB1, thereby inhibiting TAK1-
activated inﬂammatory responses in mouse macrophage cells [11]. Here
wehave shown that cross-talk betweenCaSRandTAK1-mediated inﬂam-
matory pathways was bridged by β-arrestin2 associated with TAB1 in
Caco-2 cells. These results suggest that interaction between β-arrestin2
and TAB1 inhibited TNF-α-induced TAK1 activation and subsequent
downstream signal transduction in IECs treated with γ-EC. The non-
canonical activation of CaSR by allosteric modulation may play the key
role in cross-talk with TNF-α-activated signaling event.
In conclusion, we have shown that the γ-glutamyl dipeptides γ-EC
and γ-EV can act via allosteric ligand activation of CaSR to exert intesti-
nal anti-inﬂammatory effects, and may be a novel nutraceutical or
pharmaceutical-based strategy for the prevention of inﬂammation in
IBD. The results of this study also revealed that the activation of CaSR
by γ-glutamyl dipeptides leads to the association of β-arrestin2 with
TAB1 to block activation of the TNF-α-dependent pro-inﬂammatory sig-
naling cascade through TNFR, a previously unknown function of CaSR.
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